相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pioglitazone and bladder cancer: a propensity score matched cohort study
Li Wei et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Rosiglitazone is not associated with an increased risk of bladder cancer
Chin-Hsiao Tseng
CANCER EPIDEMIOLOGY (2013)
Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes
Kanta Fujimoto et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2013)
Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
M. Ferwana et al.
DIABETIC MEDICINE (2013)
Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?
Jean-Luc Faillie et al.
DRUG SAFETY (2013)
Risk of Bladder Cancer in Diabetic Patients Treated with Rosiglitazone or Pioglitazone: A Nested Case-Control Study
Fei-Yuan Hsiao et al.
DRUG SAFETY (2013)
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Maximilian Burger et al.
EUROPEAN UROLOGY (2013)
Examining the safety of PPAR agonists - current trends and future prospects
Michele Bortolini et al.
EXPERT OPINION ON DRUG SAFETY (2013)
FDA panel advises easing restrictions on rosiglitazone
Miriam E. Tucker
BMJ-BRITISH MEDICAL JOURNAL (2013)
Flip flop policy over pioglitazone licence causes media storm in India
Soumyadeep Bhaumik
BMJ-BRITISH MEDICAL JOURNAL (2013)
Pioglitazone-Do we really need it to manage type 2 diabetes?
Binayak Sinha et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2013)
Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis
Isabelle N. Colmers et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2012)
Pioglitazone and Bladder Cancer A population-based study of Taiwanese
Chin-Hsiao Tseng
DIABETES CARE (2012)
Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis
Zhaowei Zhu et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2012)
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
A. Neumann et al.
DIABETOLOGIA (2012)
Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!
Dominique Hillaire-Buys et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
Chia-Hsuin Chang et al.
HEPATOLOGY (2012)
Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study
Ronac Mamtani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
Laurent Azoulay et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
Sun Ok Song et al.
DIABETES & METABOLISM JOURNAL (2012)
When to publish measures of disproportionality derived from spontaneous reporting databases?
Anthonius de Boer
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
Carlo Piccinni et al.
DIABETES CARE (2011)
Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan
C-H. Tseng
DIABETOLOGIA (2011)
Pioglitazone and bladder cancer
Dominique Hillaire-Buys et al.
LANCET (2011)
Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats
Keiichiro Sato et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2011)
Bladder Cancer in 2010 How Far Have We Come?
Bruce L. Jacobs et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
P. D. Home et al.
DIABETOLOGIA (2010)
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Effects of Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat
Shugo Suzuki et al.
TOXICOLOGICAL SCIENCES (2010)
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive
John Dormandy et al.
DRUG SAFETY (2009)
Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone Results from a 3-Year, Randomized, Comparator-Controlled Study in the US
Keith G. Tolman et al.
DRUG SAFETY (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Neoplastic and Non-neoplastic Changes in F-344 Rats Treated with Naveglitazar, a γ-Dominant PPAR α/γ Agonist
Gerald G. Long et al.
TOXICOLOGIC PATHOLOGY (2009)
Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
Ronald A. Lubet et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event
Gerald G. Long et al.
TOXICOLOGIC PATHOLOGY (2008)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey
John P. A. Ioannidis et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2007)
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Michael J. Bradburn et al.
STATISTICS IN MEDICINE (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
分享论文
